Background-Alternative mRNA splicing is an important mechanism for regulation of gene expression. Altered mRNA splicing occurs in association with several types of cancer, and a small number of disease-associated changes in splicing have been reported in heart disease. However, genome-wide approaches have not been used to study splicing changes in heart disease. We hypothesized that mRNA splicing is different in diseased hearts compared with control hearts. Methods and Results-We used the Affymetrix Exon array to globally evaluate mRNA splicing in left ventricular myocardial RNA from controls (nϭ15) and patients with ischemic cardiomyopathy (nϭ15). We observed a broad and significant decrease in mRNA splicing efficiency in heart failure, which affected some introns to a greater extent than others. The profile of mRNA splicing separately clustered ischemic cardiomyopathy and control samples, suggesting distinct changes in mRNA splicing between groups. Reverse transcription-polymerase chain reaction validated 9 previously unreported alternative splicing events. Furthermore, we demonstrated that splicing of 4 key sarcomere genes, cardiac troponin T (TNNT2), cardiac troponin I (TNNI3), myosin heavy chain 7 (MYH7), and filamin C, gamma (FLNC), was significantly altered in ischemic cardiomyopathy and in dilated cardiomyopathy and aortic stenosis. In aortic stenosis samples, these differences preceded the onset of heart failure. Remarkably, the ratio of minor to major splice variants of TNNT2, MYH7, and FLNC classified independent test samples as control or disease with Ͼ98% accuracy. Conclusions-Our data indicate that mRNA splicing is broadly altered in human heart disease and that patterns of aberrant RNA splicing accurately assign samples to control or disease classes. (Circ Cardiovasc Genet. 2010;3:138-146.) 
N early every human mRNA transcript is alternatively spliced, 1 and mRNA splicing is an important mechanism for generating transcriptional diversity and regulating gene expression. Tissue-specific mRNA splicing confers specialized properties to organs such as the heart. A significant proportion of gene mutations that cause human disease disrupt mRNA splicing. 2 Perturbation of mRNA splicing also may influence the natural history of acquired diseases because mRNA splicing is influenced by environmental signals and can become dysregulated in disease states. [3] [4] [5] Abnormal patterns of mRNA splicing are associated with diseases such as cancer, and splicing profiles have been shown to be effective in cancer classification. 5, 6 
Clinical Perspective on p 146
Heart failure is a leading cause of morbidity and mortality. Biomechanical loads induce gene expression changes in the heart. Heart failure also influences mRNA splicing, as indi-cated by focused studies of a small number of mRNA transcripts documenting disease-associated changes in mRNA splicing. 7, 8 For instance, human heart failure was associated with higher expression of a dominant negative variant of the key transcription factor serum response factor. 7 Ischemic cardiomyopathy (ICM) was accompanied by higher expression of an alternatively spliced variant of the sarcomere gene titin, resulting in reduced titin-derived myofibrillar stiffness. 8 However, global, genome-wide studies of differences in mRNA splicing between control and diseased myocardium have not been reported.
We hypothesized that mRNA splicing is more widely altered in human heart failure than has been appreciated based on anecdotal evidence. We used the Affymetrix Exon array to interrogate mRNA splicing in ICM (nϭ15) and nonfailing control (nϭ15) myocardium, and we used reverse transcription-polymerase chain reaction (RT-PCR) to validate findings in an independent set of 60 samples. We found substantial differences in mRNA splicing between control and diseased myocardium, including splicing of sarcomeric genes. Measures of mRNA splicing assigned samples to disease or control categories with 98% accuracy. Our results indicate that mRNA splicing is broadly perturbed in heart disease.
Methods

Patient Samples
Left ventricular (LV) myocardial samples, remote from infarcted areas, were obtained from explanted cardiomyopathy hearts at the time of transplantation, from unused transplant donor hearts, and from hearts at the time of implant or explant of an LV assist device (LVAD). Samples were frozen immediately in liquid nitrogen and stored at Ϫ80°C. Collection and analysis of tissue samples was performed under protocols approved by institutional review boards of participating institutions.
RNA Extraction and Transcript Analysis
RNA was extracted with TRIzol (Invitrogen) and further purified on RNeasy columns (Qiagen) with on-column DNase digestion. Control and disease samples were of comparable high quality when analyzed using an Experion bioanalyzer (Bio-Rad). Probe generated from RNA was hybridized to Affymetrix GeneChip Human Exon 1.0 ST (HuEx) Arrays (Gene Expression Omnibus, accession number GSE16499).
RNA was converted to cDNA by random priming, using Superscript III reverse transcriptase (Invitrogen). PCR primers are listed in the online-only data supplemental Table I 
Bioinformatic Analysis
We used several bioinformatic approaches to detect alternative splicing events and minimize false discoveries (supplemental Methods). We focused on genes with Ͻ50 exons because large exon numbers increase multiple simultaneous hypothesis testing. We defined alternative splicing events as novel if they were not present in the Alternative Splicing and Transcript Diversity database. 9 Assignment to diagnostic class was performed using a logistic regression with biomarkers based on splicing state (supplemental Methods).
Results
Systematic Alteration of RNA Splicing in ICM
We isolated total RNA from LV myocardium of patients with ICM (nϭ15) obtained at the time of heart transplantation. Control samples (nϭ15) were obtained from transplant donor hearts not used for transplantation for noncardiac reasons. Ischemic time in both groups was Ͻ2 hours. Groups were matched for sex (each 12 men and 3 women) and age (control, 50.4Ϯ1.9 years; ICM, 52.1Ϯ1.1 years). Clinical data are summarized in supplemental Table II. RNA samples were hybridized to HuEx arrays. Each exon is represented by a probeset consisting of 4 oligonucleotides. Probesets are grouped by the level of supportive evidence. The core probeset represents Refseq exons, whereas the complete probeset includes the core probeset plus probesets supported by expressed sequence tags and computationally predict d genes. There are 232 448 and 1 653 912 core and complete probesets, respectively, on the HuEx array.
Whole-gene expression levels were calculated by combining probe intensities for exons that belong to the same gene.
Consistent with previous reports, 10,11 hierarchical clustering using genes with significant differential expression accurately segregated control and ICM samples (supplemental Figure  Ia) . We did not detect significant differences in expression profiles between men and women within the control or ICM cohorts. A total of 1036 genes were differentially expressed between control and ICM (nominal PϽ0.01). The differentially expressed genes substantially overlapped with differentially expressed genes in an independent profiling study of ICM samples 12 (supplemental Figure Ib and supplemental  Table III ).
To determine whether splicing profiles similarly segregate samples by diagnosis, we used the finding isoforms using robust multichip analysis (FIRMA) method 13 on core probesets to score each gene for alternative splicing. When we selected genes with FIRMA scores that differed significantly between groups (false discovery rate Ͻ1%), ICM and control samples clustered by diagnostic label (Figure 1 ), with only 1 sample placed in the incorrect cluster. This analysis showed that splicing is systematically altered in ICM versus control samples.
Altered Splicing of Sarcomere Genes in Heart Disease
We next set out to identify genes that are differentially spliced between control and ICM groups. We analyzed complete Figure 1 . Systematic differences of mRNA splicing in ICM compared to control. Genes were scored for likelihood of alternative splicing (FIRMA score). Two-way clustering of samples and genes with significantly different FIRMA scores (false discovery rate Ͻ0.01) separated samples by diagnosis, with one misassignment. The heat map is color coded by FIRMA score (bluered, Ϫ1.9 to ϩ1.9 SDs from the mean). Genes with significantly different gene-level expression (PϽ0.05) were excluded. probeset data using 2 different statistical approaches, AS-ANOVA and MADS (microarray analysis of differential splicing), 14 to identify candidates likely to be differentially spliced between ICM and control groups. Those with significant scores by both methods (nominal PϽ0.001) are shown in supplemental Table IV . A subset of genes identified by these methods was visually inspected to identify those with likely altered splicing between groups. Among these screened candidates were several genes already known to regulate cardiomyocyte contraction or hypertrophy, including multiple sarcomere genes. Subsequently, we visually inspected all cardiomyopathy-associated sarcomere genes for potential differential splicing between groups. Two of the candidates, myosin heavy chain 7 (MYH7) and cardiac troponin T (TNNT2), are shown in Figure 2A and 2B. The TNNT2 alternative splicing event discovered here is distinct from those previously reported. 15, 16 We selected 20 candidate alternative splicing events (in 17 genes) differentially regulated in ICM for validation by RT-PCR (Table, Figure 2 , and supplemental Figure II ). Eleven involved intron retention, a relatively infrequent form of alternative splicing. 17 Additionally, 11 of these events were not previously reported in the Alternative Splicing and Transcript Diversity database. 9 To confirm these novel alternative splicing isoforms and define the mechanism of alternative splicing, we sequenced RT-PCR products using primers predicted to span exon-exon boundaries. Of the 11 novel putative splicing events, we confirmed 9 events (Table and supplemental Figure II) .
Motifs for the well-characterized splicing regulators muscleblind-like protein (MBNL1) and heterogeneous nuclear ribonucleoprotein F (hnRNP F) were significantly overrepresented in sequences flanking differentially spliced exons (supplemental Table 5 ) (PϽ10 Ϫ6 ). Based on the exon array, hnRNP F expression was downregulated in ICM by 1.3-fold (nominal P valueϭ0.0012), whereas MBNL1 expression was not significantly changed. These data suggest that muscleblind-like protein and hnRNP F participate in altered mRNA splicing observed in human heart failure.
To validate differential alternative splicing between groups, we designed semiquantitative RT-PCR assays to measure the ratio of minor and major splice isoforms and compared the ratio between groups. Of the 20 splicing events, we were successful in designing RT-PCR assays for 17. Of these 17 events, RT-PCR showed that 5 splicing events involving 4 genes were enriched in ICM compared with control (nϭ15; PϽ0.05) ( Figure 2C and 2D). Interestingly, these 4 genes are involved in sarcomere structure and function. One gene, filamin C, gamma (FLNC), a musclerestricted actin-binding protein localized to Z-discs and intercalated discs, 18, 19 exhibited higher inclusion of a previously described cassette exon ( Figure 2C and 2D). The other 3 genes, MYH7, cardiac troponin I (TNNI3), and TNNT2, underwent greater intron retention in heart failure, resulting in incorporation of in-frame stop codons ( Figure 2C and 2D). Two separate intron retention events in MYH7, referred to as MYH7-1 and MYH7-2, were higher in ICM (Figure 2A ). We performed several control experiments to verify that these intron retentions were not artifacts. First, all RT-PCR experiments were performed with and without addition of reverse transcriptase, and we observed no RT-PCR products in the absence of this enzyme (supplemental Figure IIIa and data not shown). Second, sequencing of RT-PCR products verified amplification of the intended fragment and demonstrated lack of splicing at the reference sequence exon-intron boundary in the minor isoform. Third, the intron retention products were also detected with oligo-dT-priming of reverse transcriptase reactions, indicating that the intron retention products are on polyadenylated transcripts.
We next sought to validate and extend our findings in independent samples. We used quantitative RT-PCR assays to measure minor to major isoform ratios of TNNI3, MYH7-1, MYH7-2, TNNT2, and FLNC in LV RNA from control patients and patients with ICM, idiopathic dilated cardiomyopathy (DCM), and arotic stenosis (AS) obtained at different centers from the 30 samples initially used for array analysis ( Figure 3A and 3B ). These samples were described previously. 20 For ICM, we again found higher minor to major isoform ratios of MYH7-1, MYH7-2, TNNI3, TNNT2, and FLNC, indicating that these findings are reproducible in independent patient populations and in tissue collected at different centers ( Figure 3A ). The minor to major isoform ratio of all 4 genes was also higher in DCM (PϽ0.05) and AS (PϽ0.05) ( Figure  3A and 3B), distinct forms of heart disease.
The AS samples gave us an opportunity to investigate whether mRNA splicing differences are evident before the onset of overt heart failure because 5 AS samples were from patients with heart failure (exonic forward, Ͻ50%), whereas 5 were from patients with compensated heart function (exonic forward, Ն50%). Importantly, the splicing ratios of these genes were indistinguishable between compensated and failing AS myocardium, suggesting that splicing differences are present in diseased hearts with elevated mechanical load before the onset of overt heart failure.
Conversely, we considered whether mechanical unloading of failing hearts, through placement of LVADs, was sufficient to correct abnormal splicing patterns. Similar studies of gene expression have shown that mechanical unloading normalizes expression of some, but not all genes. 21, 22 Therefore, we compared splicing of these genes before and after LVAD placement in patients with end-stage heart disease (nϭ4). RT-PCR measurement of the minor to major isoform ratio showed that LVAD placement did not significantly change splicing of these genes ( Figure 3C ). The splicing profile of these samples was consistent with the pattern observed in diseased hearts (see next section).
Exon array probes located in sarcomere gene introns identified several introns that were spliced less efficiently in heart failure. To determine whether inefficient splicing was widespread in heart failure, we used quantitative real-time RT-PCR to measure 5 arbitrarily chosen introns and 1 exon in If present in the Alternative Splicing database, then a supporting accession number is provided; otherwise, the event was considered novel. If supporting expressed sequence tags were found, up to 2 supporting accession numbers are provided. AFE indicates alternative first exon; CE, cassette exon; N, no; ND, predicted minor isoform not detected by RT-PCR; RI, retained intron; U, RTP-CR unsuccessful for quantitating minor isoform abundance; and Y, yes.
*Alternative splicing class for novel splicing events was validated by sequencing of RT-PCR products. Change in ICM was validated by RT-PCR.
each of 4 sarcomere genes (TNNT2, TNNI3, MYH7, and myosin-binding protein c3 [MYBPC3]). Comparison of ICM with control samples showed that introns were spliced out with significantly reduced efficiency in ICM. This was evident when the intron-to-exon ratio was compared between groups for all genes ( Figure 4A ) or when intron-to-exon ratios were analyzed by gene ( Figure 4B ). Analysis of each intron individually demonstrated considerable heterogeneity between samples. Despite reduced statistical power in this analysis, 2 additional introns showed statistically higher intron retention ( Figure 4C ). Both of these intron retentions were significantly higher in an independent set of ICM and control samples (nϭ5;
PϽ0.05; data not shown). These data indicate that ICM is associated with reduced splicing efficiency that affects some introns to a greater degree than others. Lower splicing efficiency in heart failure led us to ask whether splicing precision also was affected. To test this hypothesis, we developed a moderate throughput, coupled RT-PCR-capillary electrophoresis assay, to detect and measure minor variations at exon-exon junctions. For pilot studies, we examined a novel splice variant of TNNT2 that we discovered in the course of sequencing to validate TNNT2 intron retention. This variant arises from use of an alternative 5Ј splice acceptor on TNNT2 exon 7, resulting in a spliced Figure 5A ). When known ratios of wild-type and c.203_205delAAG TNNT2 variants were mixed, we were able to detect the minor variant when it was present at 5% of the major isoform ( Figure 5B ). Analysis of control and ICM samples (nϭ15) showed that the c.203_205delAAG variant comprised 5% to 10% of TNNT2 transcripts and did not significantly differ between groups ( Figure 5C and data not shown). We next used the RT-PCRcapillary electrophoresis platform to analyze 48 additional amplicons that encompass all coding exon-exon junctions of 9 sarcomere genes that are known to genetically contribute to inherited cardiomyopathies (MYBPC3, cardiac alpha actin [ACTC1], myosin light chain 2 [MYL2], myosin light chain 3 [MYL3], MYH7, cardiac troponin C [TNNC1], TNNI3, TNNT2, and alpha tropomyosin [TPM1]) for similar splice junction variation. This survey revealed only 1 other minor isoform involving fine differences of exon-exon junctions. This again occurred in TNNT2, in an amplicon (primers 3F/3R) (supplemental Table I ) that spans exons 12 to 16. The peak area of the minor isoform was Ͻ5% of the major isoform and did not vary between control and ICM groups. These data indicate that the splicing of sarcomere genes remains precise in heart failure.
Splicing Profiles Accurately Label Samples With Diagnostic Class
Splicing profiles are effective diagnostic classifiers in cancer. 5, 6 To begin to investigate the effectiveness of splicing profiles as biomarkers in heart disease, we asked whether the splicing pattern of MYH7-2, TNNT2, and FLNC was sufficient to classify samples as control or diseased. Pilot studies in which we measured minor to major splicing ratios for MYH7-2, TNNT2, and FLNC in 20 samples (control, ICM, DCM, and AS, 5 per group) by quantitative RT-PCR, suggested that splicing profiles of these genes could accurately assign control and disease diagnostic labels. Therefore, we expanded the study to include an additional 40 samples (10 per group). Principal component analysis of the 60 samples indicated that splicing profiles of these genes effectively separated control and disease samples ( Figure 6 ). Consistent with this observation, a logistic regression-based classifier trained on the 40 samples to classify control versus disease samples assigned the remaining 20 samples to control or disease groups with 100% accuracy. Similarly, Ͼ98% accuracy was attained when 20 samples were used as the training set and 40 samples as the validation set. This level of accuracy also was observed in a 5-fold cross-validation study more than 20 permutations of the combined 60 samples. One ICM sample, apparent on the principal component analysis (Figure 6, arrow) , was frequently misclassified as control. The classifier assigned both pre-and post-LVAD samples to the disease class.
Discussion
We used the Affymetrix Exon array to interrogate alternative splicing in human heart failure. To our knowledge, our data document for the first time global differences in mRNA splicing that occur in diseased hearts compared with control hearts. ICM and control samples were clustered separately by their mRNA splicing profiles. We identified 9 novel alternative splicing events, including 6 novel alternative splicing events in well-studied sarcomere genes (1 each in TNNI3, TNNT2, MYH6, and MYBPC3 and 2 in MYH7). Moreover, we showed that splicing of 4 sarcomere genes, FLNC, TNNI3, TNNT2, and MYH7, was different in diseased hearts compared with control hearts. These changes in splicing likely occur before the onset of overt heart failure because they also were altered in patients with AS with LV hypertrophy but preserved ventricular function. In addition, LVAD placement in failing hearts did not correct aberrant splicing of these genes, suggesting that molecular changes that lead to abnormal splicing of these genes are not readily reversible by mechanical unloading.
Differences in minor to major isoform ratios of specific genes were highly characteristic of heart disease such that the ratio of the 3 splice variants of MYH7, TNNT2, and FLNC assigned samples into normal and disease classes with Ͼ98% accuracy. The classification accuracy of splicing profiles suggests that splicing ratios may be developed as useful diagnostic and prognostic biomarkers in heart failure. mRNA expression profiling of myocardial samples has been investigated as a diagnostic and prognostic tool in heart disease, and initial studies indicate that transcriptional profiles predict prognosis and disease severity in ICM. 23, 24 Our results suggest that measurement of mRNA splicing may be a useful adjunct to gene-level measurements of transcript abundance. Further proof of concept will involve identifying splicing events that accurately label samples with disease class, which has been used as further proof of concept of prognostic utility of gene expression profiles. 25 Although the 3 splicing events at MYH7, TNNT2, and FLNC were not able to discriminate among different subtypes of heart disease, this is not unexpected because they were discovered in a screen of splicing events differentially regulated in control versus ICM. Screening for splicing events differentially regulated between disease classes may identify splicing events that distinguish between disease classes.
A surprising finding of the exon array, validated by RT-PCR, was the high frequency of intron retention events among splicing events differentially regulated between ICM and control hearts. Consequently, we surveyed 20 unselected introns of sarcomere genes and found significantly reduced excision of multiple introns in ICM. This finding suggests that ICM is accompanied by widespread reduction of splicing efficiency. This reduction in intron splicing affected some introns to a greater degree than others. Although mRNA splicing efficiency was lower in heart failure, the precision of splicing was not significantly affected, as demonstrated by our survey of all coding exon-exon junctions of 8 sarcomere genes for variation in splice donor or acceptor sites.
We validated differential splicing of 4 sarcomere genes, MYH7, TNNI3, TNNT2, and FLNC, in diseased versus normal myocardium. FLNC is a large, rod-like actin-binding protein expressed in striated muscles and localized to Z-disks and intercalated discs. 18, 19 Mutation of FLNC caused DCM. FLNC contains a cassette exon encoding a flexible hinge region. 18 In normal muscle, this cassette exon is largely spliced out to yield the FLNC (ϪH1) variant. 26 We show that the FLNC variant that includes this flexible hinge region FLNC (ϩH1) increases in heart disease, potentially altering structure or function of Z-disks, key signaling centers in cardiomyocytes.
The sarcomere genes MYH7, TNNI3, and TNNT2 exhibited increased intron retention in diseased myocardium. The fraction of total transcripts with retained introns was low by quantitative PCR for MYH7-2 (control hearts, 0.1%; ICM hearts, 0.3%), but the fold increase in transcripts with retained introns was substantial (up to 15-fold) (Figure 4) . The functional significance of increased abundance of incompletely spliced transcripts will require further investigation. Intron retention also results in transcripts containing premature stop codons, which may reduce effective translation, cause nonsense-mediated decay, produce incomplete proteins that have dominant negative activity, 27 or contribute to protein aggregates seen in some forms of heart disease.
In addition to alternative splicing of TNNT2 involving retention of the intron following exon 7, we found a novel TNNT2 isoform generated by alternative splice acceptor usage at the 5Ј boundary of exon 7. This finding confirmed a prior suggestion that there may be 2 closely space splice acceptors at this location. 28 Variable 5Ј splice acceptor usage resulted in 5% to 10% of adult TNNT2 transcripts encoding a protein lacking Asp41. Expression of this variant was not different in ICM. The N-terminus of TNNT2 encoded by exons 2 to 7 is less well conserved than the C-terminus and undergoes developmentally regulated alternative splicing 29 that influences differential sensitivity of the fetal heart to hypoxia and acidosis. 30 The importance of this region of TNNT is underscored by an intron 3 polymorphism that alters splicing of exon 4 and predisposes to LV hypertrophy. 31 Several limitations of this study should be noted. First, although the exon array revealed interesting aspects of mRNA splicing in heart disease, it has limited resolution and sensitivity. Perhaps as a result of this limitation, previously reported alternative splicing of titin 8 and TNNT2 exons 4 to 6 16, 32 were not detected by our exon array analysis. Future studies might take advantage of the recently reported application of massively parallel sequencing strategies to sequence the entire mRNA transcriptome (mRNA-seq), 1, 17 which permits quantitative delineation of alternative splicing at nucleotide resolution. Second, our global analysis compared ICM with control myocardium; therefore, it is not surprising that the splicing events arising from this screen were not effective in differentiating between disease states. Additional studies of mRNA splicing in different heart disease classes will be required to provide further proof of principle that myocardial splicing-related biomarkers contain this type of clinically important information.
In conclusion, we showed that mRNA splicing is altered in human heart failure. We identified novel splicing events and heart failure associated differences in mRNA splicing of several key sarcomere genes. Our data demonstrate reduction of mRNA splicing efficiency in heart failure. These changes in mRNA splicing may contribute to pathogenesis of heart disease. In addition, mRNA splicing patterns accurately classified samples by diagnostic label, providing proof of concept that mRNA splicing patterns may have utility as diagnostic or prognostic markers in heart disease. 
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